PL2938351T3 - Krótko działające polipeptydy czynnika VII - Google Patents

Krótko działające polipeptydy czynnika VII

Info

Publication number
PL2938351T3
PL2938351T3 PL13867801T PL13867801T PL2938351T3 PL 2938351 T3 PL2938351 T3 PL 2938351T3 PL 13867801 T PL13867801 T PL 13867801T PL 13867801 T PL13867801 T PL 13867801T PL 2938351 T3 PL2938351 T3 PL 2938351T3
Authority
PL
Poland
Prior art keywords
short
factor vii
acting factor
vii polypeptides
polypeptides
Prior art date
Application number
PL13867801T
Other languages
English (en)
Inventor
Maxine Bauzon
Terry Hermiston
Original Assignee
Coagulant Therapeutics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51022016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2938351(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coagulant Therapeutics Corporation filed Critical Coagulant Therapeutics Corporation
Publication of PL2938351T3 publication Critical patent/PL2938351T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
PL13867801T 2012-12-24 2013-12-23 Krótko działające polipeptydy czynnika VII PL2938351T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261745674P 2012-12-24 2012-12-24
US201361787026P 2013-03-15 2013-03-15
EP13867801.6A EP2938351B8 (en) 2012-12-24 2013-12-23 Short-acting factor vii polypeptides
PCT/US2013/077405 WO2014105784A1 (en) 2012-12-24 2013-12-23 Short-acting factor vii polypeptides

Publications (1)

Publication Number Publication Date
PL2938351T3 true PL2938351T3 (pl) 2020-03-31

Family

ID=51022016

Family Applications (3)

Application Number Title Priority Date Filing Date
PL13867801T PL2938351T3 (pl) 2012-12-24 2013-12-23 Krótko działające polipeptydy czynnika VII
PL16196780T PL3165232T3 (pl) 2012-12-24 2013-12-23 Krótko działające polipeptydy czynnika VII
PL19181784.0T PL3572090T3 (pl) 2012-12-24 2013-12-23 Polipeptydy czynnika vii o krótkim działaniu

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL16196780T PL3165232T3 (pl) 2012-12-24 2013-12-23 Krótko działające polipeptydy czynnika VII
PL19181784.0T PL3572090T3 (pl) 2012-12-24 2013-12-23 Polipeptydy czynnika vii o krótkim działaniu

Country Status (21)

Country Link
US (5) US20150344863A1 (pl)
EP (3) EP3165232B1 (pl)
JP (3) JP6566869B2 (pl)
KR (2) KR102111934B1 (pl)
CN (2) CN105025913B (pl)
AU (2) AU2013370522B2 (pl)
BR (1) BR112015015182B1 (pl)
CA (2) CA3185756A1 (pl)
DK (3) DK2938351T3 (pl)
ES (3) ES2747726T3 (pl)
HK (1) HK1216855A1 (pl)
IL (2) IL239345B (pl)
MX (3) MX380585B (pl)
NZ (1) NZ708873A (pl)
PE (2) PE20151206A1 (pl)
PL (3) PL2938351T3 (pl)
SA (1) SA517380867B1 (pl)
SG (2) SG11201504986QA (pl)
TW (3) TWI681968B (pl)
WO (1) WO2014105784A1 (pl)
ZA (1) ZA201505315B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100267508B1 (ko) 1998-07-13 2001-01-15 김충섭 다겹지 제조용 접착제 및 이를 이용한 다겹지 제조방법
WO2014105784A1 (en) 2012-12-24 2014-07-03 Bayer Healthcare Llc Short-acting factor vii polypeptides
TW201629215A (zh) * 2014-09-30 2016-08-16 拜耳保健有限責任公司 使用凝血酶之組成物及治療方法
KR101755838B1 (ko) 2015-09-09 2017-07-07 현대자동차주식회사 엔진 예열장치 및 그 예열방법
WO2018052827A1 (en) 2016-09-13 2018-03-22 Bayer Healthcare Llc Factor viia glycoforms
KR102120921B1 (ko) * 2017-02-10 2020-06-10 주식회사 일리아스바이오로직스 Gba 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 고셔병 예방 및 치료용 약학적 조성물
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3008252A (en) 1959-02-02 1961-11-14 Beatrice V Robinson Puffed sleeve ironer
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
FR2632524B1 (fr) 1988-06-09 1992-03-13 Fondation Nale Transfusion San Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament
PL206148B1 (pl) 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
CA2409674C (en) 2000-05-23 2010-05-11 Neurologix, Inc. Glutamic acid decarboxylase (gad) based delivery systems
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US20050221335A1 (en) 2001-12-14 2005-10-06 Anthony Kavanagh Reporter gene
RU2004134726A (ru) * 2002-04-30 2005-06-10 Максиджен Холдингз Лтд. (Ky) Варианты полипептида фактора vii или viia
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
CA2519873C (en) * 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
ATE458057T1 (de) * 2003-06-19 2010-03-15 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
ES2381110T3 (es) * 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
AU2005215889B9 (en) 2004-02-13 2011-11-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
EP1629096A1 (en) 2004-05-10 2006-03-01 BASF Plant Science GmbH Methods for assembling multiple expression constructs
EP1761630A2 (en) 2004-06-21 2007-03-14 Novo Nordisk Health Care AG Glycosylation-disrupted factor vii variants
KR20070110902A (ko) 2005-03-11 2007-11-20 프레제니우스 카비 도이치란트 게엠베하 비활성 출발 물질로부터 생물활성 당단백질의 생산
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
DK1907540T3 (da) * 2005-07-22 2013-03-11 Bayer Healthcare Llc Aktivering af faktor VII i opløsning
CN102719508A (zh) * 2005-08-19 2012-10-10 诺和诺德公司 糖基聚乙二醇化的因子vii和因子viia
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1971368A4 (en) * 2005-11-08 2009-08-05 Astellas Pharma Inc COMPOSITIONS AND METHODS FOR TREATING THROMBOCYTOPENIA
EP2016072B1 (en) * 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
US7532621B2 (en) 2006-08-30 2009-05-12 Cornell Research Foundation, Inc. Lateral error correction for time-critical multicast
JP5876208B2 (ja) * 2006-12-15 2016-03-02 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
KR101427434B1 (ko) 2006-12-20 2014-09-19 스미또모 가가꾸 가부시키가이샤 편광판 및 액정 표시 장치
JP2010514448A (ja) 2006-12-28 2010-05-06 セントコア・オーソ・バイオテツク・インコーポレーテツド アシアリル化免疫グロブリンを生成するための方法およびベクター
AU2008219305B2 (en) 2007-02-20 2013-08-22 Dsm Ip Assets B.V. Novel sialidase
WO2008134665A1 (en) 2007-04-26 2008-11-06 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
EP2930245B1 (en) 2007-10-12 2017-11-22 Sigma-Aldrich Co. LLC Cell line and methods for improved glycoprotein sialylation
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP3225252A1 (en) * 2008-05-02 2017-10-04 Laboratoire Français du Fractionnement et des Biotechnologies Treatment of bleeding with low half-life fibrinogen
JP2010022253A (ja) * 2008-07-17 2010-02-04 Kaneka Corp アシアロ糖鎖化合物の作製方法
CN102307562A (zh) 2008-12-05 2012-01-04 加利福尼亚大学董事会 处理痤疮丙酸杆菌的方法和组合物
US8400974B2 (en) * 2009-07-30 2013-03-19 Apple Inc. Methods and apparatus for providing dynamic information in a wireless information channel
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
WO2013017555A1 (en) * 2011-08-01 2013-02-07 Lfb-Biotechnologies Factor vii compositions with specific glycosylation for controlled half-life
WO2014105784A1 (en) 2012-12-24 2014-07-03 Bayer Healthcare Llc Short-acting factor vii polypeptides

Also Published As

Publication number Publication date
NZ708873A (en) 2019-11-29
EP3572090A1 (en) 2019-11-27
HK1216855A1 (zh) 2016-12-09
TW201431876A (zh) 2014-08-16
JP2017071608A (ja) 2017-04-13
KR20150127573A (ko) 2015-11-17
US10717970B2 (en) 2020-07-21
CA3185756A1 (en) 2014-07-03
KR102047235B1 (ko) 2019-11-22
DK2938351T3 (da) 2019-09-23
JP2019213540A (ja) 2019-12-19
PE20211303A1 (es) 2021-07-20
EP2938351B8 (en) 2019-07-31
BR112015015182A2 (pt) 2019-07-30
AU2013370522A1 (en) 2015-07-09
DK3165232T3 (da) 2019-09-16
JP6566869B2 (ja) 2019-08-28
US10273466B2 (en) 2019-04-30
PL3572090T3 (pl) 2023-04-11
JP2016507506A (ja) 2016-03-10
ES2936485T3 (es) 2023-03-17
JP6363677B2 (ja) 2018-07-25
SG10201710593UA (en) 2018-02-27
EP2938351A1 (en) 2015-11-04
EP2938351A4 (en) 2016-08-24
US20210002624A1 (en) 2021-01-07
ZA201505315B (en) 2022-11-30
MX380585B (es) 2025-03-12
DK3572090T3 (da) 2023-01-09
PL3165232T3 (pl) 2019-12-31
ES2746116T3 (es) 2020-03-04
TW202026309A (zh) 2020-07-16
SG11201504986QA (en) 2015-07-30
TW201920254A (zh) 2019-06-01
US20140363419A1 (en) 2014-12-11
SA517380867B1 (ar) 2020-06-10
US11530401B2 (en) 2022-12-20
KR20190072686A (ko) 2019-06-25
AU2013370522A2 (en) 2016-10-06
CA2896057A1 (en) 2014-07-03
CA2896057C (en) 2023-03-14
BR112015015182B1 (pt) 2023-12-26
EP2938351B1 (en) 2019-06-26
US20160376578A1 (en) 2016-12-29
TWI708783B (zh) 2020-11-01
IL239345A0 (en) 2015-07-30
EP3572090B1 (en) 2022-12-14
CN105025913B (zh) 2025-04-04
KR102111934B1 (ko) 2020-05-18
US20150344863A1 (en) 2015-12-03
CN107099522A (zh) 2017-08-29
TWI681968B (zh) 2020-01-11
MX2021002985A (es) 2021-05-14
IL239345B (en) 2020-04-30
IL273559A (en) 2020-05-31
AU2019202663B2 (en) 2020-09-10
IL273559B (en) 2022-04-01
DK3572090T5 (da) 2024-09-02
ES2747726T3 (es) 2020-03-11
EP3165232B1 (en) 2019-07-10
CN105025913A (zh) 2015-11-04
NZ749488A (en) 2021-09-24
AU2013370522B2 (en) 2019-01-17
US20230295596A1 (en) 2023-09-21
MX2015007712A (es) 2015-09-07
MX387579B (es) 2025-03-18
PE20151206A1 (es) 2015-09-04
TWI743542B (zh) 2021-10-21
EP3165232A1 (en) 2017-05-10
WO2014105784A1 (en) 2014-07-03
AU2019202663A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
IL291571A (en) cx3cr1 binding polypeptides
IL254716B (en) Zinc-lysine conjugate
GB2521524B (en) Chromatographic materials
ZA201309174B (en) Polypeptides
ZA201503358B (en) Structure
GB201220474D0 (en) Polypeptides
GB201213567D0 (en) Biomarkers
GB201201100D0 (en) Polypeptides and methods
IL273559B (en) Factor vii polypeptides for short-term use
PL2875059T3 (pl) Materiały pośrednie zawierające poliizocyjanuran
GB201319035D0 (en) Spolier structure
GB201210565D0 (en) Biomarkers
HUP1300640A2 (en) Belt-mounting structure
EP2871919A4 (en) STRUCTURE
EP2826412A4 (en) PROBE
GB201214866D0 (en) Probe
EP2804845A4 (en) LITHIUM ION CONDUCTIVE MATERIALS
GB201203948D0 (en) Detecting polypeptides
HUE047406T2 (hu) Polipeptidek
GB201210303D0 (en) Polypeptides and methods
GB201206241D0 (en) Quartermaster
PH32012000232S1 (en) Can
PH32012000233S1 (en) Can
PH32012000234S1 (en) Can